Neurocrine Biosciences NBIX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's accounts payable?
- Neurocrine Biosciences (NBIX) reported accounts payable of $773M in Q1 2026.
- How has Neurocrine Biosciences's accounts payable changed year-over-year?
- Neurocrine Biosciences's accounts payable increased by 62.7% year-over-year, from $475.2M to $773M.
- What is the long-term trend for Neurocrine Biosciences's accounts payable?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's accounts payable has grown at a 31.9% compound annual growth rate (CAGR), from $168.7M to $674.3M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.